Navigation Links
Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
Date:7/8/2009

CAMBRIDGE (UK). 8th July 2009 / b3c newswire / - Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.

We are extremely pleased with the outcome of this initial clinical study with FX125L said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L.


About Funxional Therapeutics Ltd.
Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) which focuses on novel anti-inflammatory therapies. FXT is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge University. FXT has research and office facilities in Cambridge.
For more information about FXT, please visit our web site (www.funxionaltherapeutics.com) or contact us by e-mail ( info@funxionaltherapeutics.com ).

About BSCIs

BSCIs are anti-inflammatory compounds with an entirely novel mechanism of action that involves the selective interaction with a well-characterized receptor, resulting in a potent inhibition of inflammatory cell migration. The compounds are anticipated to have broad applicability in inflammatory diseases.
BSCIs are one of the three proprietary technology platforms in FXTs portfolio all of which originated in the University of Cambridge. BSCIs were discovered based upon a strategy that exploits functional screening to develop novel new classes of drugs. FX125L is the lead drug candidate in this novel class, while other BSCIs have been identified as back up molecules or as candidates for development as topical anti-inflammatory agents.

Contact

Konstantinos Efthymiopoulos

CEO of Funxional Therapeutics

+44 1223 451095


'/>"/>
b3c newswire

Related biology news :

1. In troubled economic times, BioSquare 2009 successfully serves as business and innovation starter
2. Salk researchers successfully reprogram keratinocytes attached to a single hair
3. Model successfully predicts large river system fish diversity
4. Scientists successfully treat new mouse model of inflammatory bowel disease
5. Researchers successfully simulate photosynthesis and design a better leaf
6. MIT Holding, Georgia Southern University, and MEVLABS successfully test the PROVECTOR
7. A new milestone in the GMES Space Component Program successfully achieved
8. Life on Mars pregnancy test successfully launched
9. DOE Joint Genome Institute completes soybean genome
10. L-1 Identity Solutions Completes Acquisition of the ID Systems Business from Digimarc Corporation
11. bioMETRX, Inc. Completes Exclusive Licensing Agreement With EZ Print, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology: